Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated IκB kinase
- 202 Downloads
Curcumin is a natural polyphenolic derogate extracted from spice turmeric, exhibiting anti-inflammatory and chemopreventive activities. It was described to interact with the signalosome-associated kinases and the proteasome-ubiquitin system, which both are involved in the osteoclastogenesis. Thus, we hypothesized that curcumin could diminish osteoclast differentiation and function.
For the experiments considering osteoclast differentiation and resorptional activities, preosteoclasts were cultured for 4 weeks and treated with curcumin at subapoptotic dosages. Derived mature osteoclasts were identified as large, multinucleated cells with expression of tartrate-resistant acid phosphatase activity. Formation of resorption lacunae, a hallmark of osteoclast activity, was quantified using dentine pits and light microscopy. The signaling pathways were examined by ELISA-based methods and by immunoblotting.
Both 1 and 10 μM curcumin abrogated osteoclast differentiation (by 56 and 81%) and function (by 56 and 99%) (P < 0.05) dose-dependently. The effects were accompanied by the inhibition of IκB phosphorylation and NF-κB activation. In contrast, subtoxic doses did not have any significant effects on proteasome inhibition.
This manuscript is the first report that describes the effects of curcumin toward human osteoclastogenesis, and builds the framework for clinical trials of curcumin in the treatment of cancer-induced lytic bone disease.
KeywordsProteasome Curcumin NF-κB IκB Osteoclast Cancer
This study was supported by the Deutsche Forschungsgemeinschaft (DFG Klinische Forschergruppe KFO 105).
- Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M et al (2002) Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol 63:1709–1716. doi: 10.1016/S0006-2952(02)00931-0 PubMedCrossRefGoogle Scholar
- Commandeur JN, Vermeulen NP (1996) Cytotoxicity and cytoprotective activities of natural compounds. The case of curcumin. Xenobiotica 26:667–680Google Scholar
- Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL (2000) The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 141:4768–4776. doi: 10.1210/en.141.12.4768 PubMedCrossRefGoogle Scholar
- Hecht M, Heider U, Kaiser M, von Metzler I, Sterz J, Sezer O (2007) Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br J Haematol 138:446–458. doi: 10.1111/j.1365-2141.2007.06665.x PubMedCrossRefGoogle Scholar
- Hecht M, von Metzler I, Sack K, Kaiser M, Sezer O (2008) Myeloma cell–osteoclast interaction stimulates expression of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA) through activation of p38 MAPK and STAT3. Exp Cell Res 314:1082–1093. doi: 10.1016/j.yexcr.2007.10.021 PubMedCrossRefGoogle Scholar
- Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC et al (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382–4389. doi: 10.1210/en.140.10.4382 PubMedCrossRefGoogle Scholar
- Hofbauer LC, Neubauer A, Heufelder AE (2001) Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92:460–470. doi:10.1002/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-DPubMedCrossRefGoogle Scholar